Background Image

Burroughs-Wellcome Fund - Reg. Science

Manager: Nicole Gadway
Priority: Open


Incorporated in 1955 in NY.

Silas Burroughs and Henry Wellcome, American pharmacists, recognized that the introduction of "compressed" medicines-pills-in America offered great opportunity for expansion and success abroad. The two men formed their partnership in London in 1880, and their enterprise--known as Burroughs Wellcome and Co.--prospered. After Silas Burroughs died in 1895, Henry Wellcome directed the growth of the company into an international network. He also established the industry's first research laboratories In 1924, Wellcome consolidated all of the company's holdings, both in England and abroad, under a corporate umbrella that he named the Wellcome Foundation Ltd. When he died in 1936, his will called for vesting all of the corporate shares in a new entity--the Wellcome Trust. The trust's charge was to devote all of its income to research in medicine and allied sciences and to the maintenance of research museums and libraries dedicated to these fields In 1955, Sir Henry Dale, one of the trust's original trustees and its chair. for 21 years, and William N. Creasy, president and chair. of Burroughs Wellcome Co.-USA, envisioned a U.S. extension, and so was born the Burroughs Wellcome Fund, which would be supported by the U.S. company. Both men saw the fund as a natural extension of Henry Wellcome's will and its intent, as well as an acknowledgment of his native land and the great success of the American branch of the Wellcome enterprise. In 1993, BWF received from the Wellcome Trust a $400 million gift that altered the fund's very nature. The gift enabled the fund to become a completely independent foundation, with no direct ties to its founding company.


biology, medical research


Giving limited to the U.S. and Canada.

No grants to individuals, or for building or endowment funds, equipment, operating budgets, continuing support, annual campaigns, deficit financing, publications, conferences, or matching gifts; no loans.


Year ended 2013-08-31

Assets: $719,935,278 (market value)

Expenditures: $39,319,875

Total giving: $28,407,990

Qualifying distributions: $33,322,096

Giving activities include:

$28,407,990 for 699 grants (high: $359,000; low: $500)


The following grants are a representative sample of this grantmaker's funding activity:

  • $700,000 to Harvard University, Cambridge, MA, in 2012. For grant to School of Medicine in Boston for characterization of non-coding RNAs in pancreatic adenocarcinoma
  • $700,000 to Stanford University, Stanford, CA, in 2012. For Function of the plastid organelle in P. falciparum: beyond isoprenoid precursor biosynthesis and blood stage
  • $700,000 to University of Chicago, Chicago, IL, in 2012. For Identification of chromosomal aberrations that cooperate with the human papillomavirus to cause cancer
  • $700,000 to University of Texas Southwestern Medical Center, Dallas, TX, in 2012. For akt-mediated regulation of autophagy and tumorigenesis through formation of a beclin 1/keratin intermediate filament complex
  • $180,000 to Hyde County Schools, Swanquarter, NC, in 2012. For STEM 4 ME! Academy
  • $180,000 to North Carolina School of Science and Mathematics Foundation, Durham, NC, in 2012. For Step Up to STEM
  • $179,931 to Eno River Association, Durham, NC, in 2012. For iWalk the Eno II and Outdoor Science Labs: Year-round Science, Engineering, and Nature Inquiries
  • $178,500 to North Carolina State University, Raleigh, NC, in 2012. For The Engineering Place
  • $28,950 to Webb A. Murray Elementary School, Hickory, NC, in 2012. For Aventuras de Ciencia (Adventures in Science)
  • $10,000 to University of California, Los Angeles, CA, in 2012. For Nanopatterning Proteins